keyword
MENU ▼
Read by QxMD icon Read
search

Ovaring

keyword
https://www.readbyqxmd.com/read/27769273/communicating-brca-research-results-to-patients-enrolled-in-international-clinical-trials-lessons-learnt-from-the-ago-ovar-16-study
#1
David J Pulford, Philipp Harter, Anne Floquet, Catherine Barrett, Dong Hoon Suh, Michael Friedlander, José Angel Arranz, Kosei Hasegawa, Hiroomi Tada, Peter Vuylsteke, Mansoor R Mirza, Nicoletta Donadello, Giovanni Scambia, Toby Johnson, Charles Cox, John K Chan, Martin Imhof, Thomas J Herzog, Paula Calvert, Pauline Wimberger, Dominique Berton-Rigaud, Myong Cheol Lim, Gabriele Elser, Chun-Fang Xu, Andreas du Bois
BACKGROUND: The focus on translational research in clinical trials has the potential to generate clinically relevant genetic data that could have importance to patients. This raises challenging questions about communicating relevant genetic research results to individual patients. METHODS: An exploratory pharmacogenetic analysis was conducted in the international ovarian cancer phase III trial, AGO-OVAR 16, which found that patients with clinically important germ-line BRCA1/2 mutations had improved progression-free survival prognosis...
October 21, 2016: BMC Medical Ethics
https://www.readbyqxmd.com/read/27717889/ovar-drb1-haplotypes-2001-and-0301-are-associated-with-sheep-growth-and-ewe-lifetime-prolificacy
#2
Mehmet Ulas Cinar, Michelle R Mousel, Lynn M Herrmann-Hoesing, J Bret Taylor, Stephen N White
BACKGROUND: The major histocompatibility complex (MHC) is an organized cluster of tightly linked vertebrate genes with immunological and non-immunological functions. While the important MHC gene DRB1 has been examined in regard to many sheep infectious disease traits, only one study, based on microsatellite markers, has previously examined DRB1 and sheep production traits. Furthermore, to our knowledge no studies have examined DRB1 relationship with lifetime ewe prolificacy traits. Therefore, we analyzed association between the presence of DRB1 SNP haplotypes with internationally recognized standard names and production traits including growth and lifetime prolificacy in 370 Rambouillet, Columbia, and Polypay sheep...
October 4, 2016: Gene
https://www.readbyqxmd.com/read/27630715/corrigendum-to-the-efficacy-of-inositol-and-n-acetyl-cysteine-administration-ovaric-hp-in-improving-the-ovarian-function-in-infertile-women-with-pcos-with-or-without-insulin-resistance
#3
Angela Sacchinelli, Roberta Venturella, Daniela Lico, Annalisa Di Cello, Antonella Lucia, Erika Rania, Roberto Cirillo, Fulvio Zullo
[This corrects the article DOI: 10.1155/2014/141020.].
2016: Obstetrics and Gynecology International
https://www.readbyqxmd.com/read/27561452/prognostic-factors-in-young-ovarian-cancer-patients-an-analysis-of-four-prospective-phase-iii-intergroup-trials-of-the-ago-study-group-gineco-and-nsgo
#4
M Klar, A Hasenburg, M Hasanov, F Hilpert, W Meier, J Pfisterer, E Pujade-Lauraine, J Herrstedt, A Reuss, A du Bois
OBJECTIVES: We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients < and >40 years of age with advanced epithelial ovarian cancer. METHODS: A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients <40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles...
October 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27327375/snp-discovery-in-candidate-adaptive-genes-using-exon-capture-in-a-free-ranging-alpine-ungulate
#5
Gretchen H Roffler, Stephen J Amish, Seth Smith, Ted Cosart, Marty Kardos, Michael K Schwartz, Gordon Luikart
Identification of genes underlying genomic signatures of natural selection is key to understanding adaptation to local conditions. We used targeted resequencing to identify SNP markers in 5321 candidate adaptive genes associated with known immunological, metabolic and growth functions in ovids and other ungulates. We selectively targeted 8161 exons in protein-coding and nearby 5' and 3' untranslated regions of chosen candidate genes. Targeted sequences were taken from bighorn sheep (Ovis canadensis) exon capture data and directly from the domestic sheep genome (Ovis aries v...
September 2016: Molecular Ecology Resources
https://www.readbyqxmd.com/read/27269942/double-blind-placebo-controlled-randomized-phase-iii-trial-evaluating-pertuzumab-combined-with-chemotherapy-for-low-tumor-human-epidermal-growth-factor-receptor-3-mrna-expressing-platinum-resistant-ovarian-cancer-penelope
#6
Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier, Nicoletta Colombo, Domenica Lorusso, Petronella Ottevanger, Maria Bjurberg, Christian Marth, Pilar Barretina-Ginesta, Ignace Vergote, Anne Floquet, Josep M Del Campo, Sven Mahner, Lydie Bastière-Truchot, Nicolas Martin, Mikkel Z Oestergaard, Astrid Kiermaier, Carmen Schade-Brittinger, Sandra Polleis, Andreas du Bois, Antonio Gonzalez-Martin
PURPOSE: The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis. PATIENTS AND METHODS: Eligible patients had ovarian carcinoma that progressed during or within 6 months of completing four or more platinum cycles, centrally tested low tumor HER3 mRNA expression (concentration ratio ≤ 2...
July 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26941446/statement-of-the-ago-kommission-ovar-ago-study-group-noggo-ago-austria-and-ago-switzerland-regarding-the-use-of-hyperthermic-intraperitoneal-chemotherapy-hipec-in-ovarian-cancer
#7
P Harter, A du Bois, S Mahner, J Pfisterer, O Ortmann, C Marth, D Fink, F Hilpert, U Wagner, J Sehouli
The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.
February 2016: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/26927118/a-novel-cooperative-opportunistic-routing-scheme-for-underwater-sensor-networks
#8
Seyed Mohammad Ghoreyshi, Alireza Shahrabi, Tuleen Boutaleb
Increasing attention has recently been devoted to underwater sensor networks (UWSNs) because of their capabilities in the ocean monitoring and resource discovery. UWSNs are faced with different challenges, the most notable of which is perhaps how to efficiently deliver packets taking into account all of the constraints of the available acoustic communication channel. The opportunistic routing provides a reliable solution with the aid of intermediate nodes' collaboration to relay a packet toward the destination...
2016: Sensors
https://www.readbyqxmd.com/read/26827718/translational-otolith-ocular-reflex-during-off-vertical-axis-rotation-in-humans
#9
Gilles Clément, Scott J Wood
Two characteristics of otolith-ocular responses - linear vestibulo-ocular reflex and vergence - were examined during constant velocity off-vertical axis rotation (OVAR) in the dark. Sixteen subjects were rotated about their longitudinal axis when tilted 30° relative to the direction of gravity. Rotational velocities were 36 and 288/s corresponding to frequencies of 0.1 and 0.8Hz, respectively. Subjects were asked to imagine stationary targets located at 0.5m, 1m, and 2m in the straight-ahead direction. Binocular eye movements were recorded in the dark using infrared videography...
March 11, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/26740259/brca1-2-mutations-associated-with-progression-free-survival-in-ovarian-cancer-patients-in-the-ago-ovar-16-study
#10
RANDOMIZED CONTROLLED TRIAL
Philipp Harter, Toby Johnson, Dominique Berton-Rigaud, Sang-Yoon Park, Michael Friedlander, Josep M Del Campo, Muneaki Shimada, Frédéric Forget, Mansoor R Mirza, Nicoletta Colombo, Claudio Zamagni, John K Chan, Martin Imhof, Thomas J Herzog, Dearbhaile O'Donnell, Florian Heitz, Karen King, Sandy Stinnett, Catherine Barrett, Minesh Jobanputra, Chun-Fang Xu, Andreas du Bois
OBJECTIVE: AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS. METHODS: Of 940 AGO-OVAR 16 participants, 664 had BRCA1/2 exon sequencing data (pazopanib, n=335; placebo, n=329). A Cox model was used to test the association between genetic variants and PFS...
March 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/26597305/plasticity-of-the-human-vestibulo-ocular-reflex-during-off-vertical-axis-rotation
#11
Masatoshi Akutsu, Akemi Sugita-Kitajima, Koshi Mikami, Izumi Koizuka
OBJECTIVE: We investigated whether adaptive plasticity of the vestibulo-ocular reflex in humans occurs in response to visual-vestibular conflict stimulation during rotation about a 30° incline (off-vertical earth axis rotation, OVAR). METHODS: Subjects were 26 healthy adults (17 males and 9 females), ranging in age from 22 to 33 years (mean: 24.4) with no history of neurotological symptoms. Each testing session consisted of a pre-test, an adaptation period, and a post-test...
August 2016: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/26590673/standard-first-line-chemotherapy-with-or-without-nintedanib-for-advanced-ovarian-cancer-ago-ovar-12-a-randomised-double-blind-placebo-controlled-phase-3-trial
#12
RANDOMIZED CONTROLLED TRIAL
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor R Mirza, Giovanni Scambia, Werner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter
BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. METHODS: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose...
January 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26556905/statement-by-the-kommission-ovar-of-the-ago-the-new-figo-and-who-classifications-of-ovarian-fallopian-tube-and-primary-peritoneal-cancer
#13
I Meinhold-Heerlein, C Fotopoulou, P Harter, C Kurzeder, A Mustea, P Wimberger, S Hauptmann, J Sehouli
More than 25 years after the last revision, in 2012 the FIGO Oncology Committee began revising the FIGO classification for staging ovarian, Fallopian tube and primary peritoneal cancers. The new classification has become effective with its publication at the beginning of 2014. Following recent findings on the pathogenesis of ovarian, Fallopian tube and primary peritoneal cancer and reflecting standard clinical practice, the three entities have now been classified uniformly. The histological subtype is included (high-grade serous - HGSC; low-grade serous - LGSC; mucinous - MC; clear cell - CCC; endometrioid - EC)...
October 2015: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/26246876/effect-of-surgical-removal-of-endometriomas-on-cyclic-and-non-cyclic-pelvic-pain
#14
Murat Api, Aysen Telce Boza, Semra Kayatas, Mustafa Eroglu
BACKGROUND: Endometriosis is a complex disease with a spectrum of pain symptoms from mild dysmenorrhea to debilitating pelvic pain. There is no concrete evidence in the literature whether endometriotic cyst per se, causes pain spectrum related to the disease. The aim of the present study was to evaluate the effect of surgical removal of endome- triomas on pain symptoms. MATERIALS AND METHODS: In this prospective, observational, before-after study, which was conducted between March 2012 and January 2013 in Training and Research Hospital,Adana, Turkey, a total of 23 patients including 16 sexually active and 7 vir- gin symptomatic women were questioned for non-cyclic pelvic pain (NCPP), intensity of the NCPP, presence of cyclic dysmenorrhea, and dyspareunia before and after the endometrioma operation...
July 2015: International Journal of Fertility & Sterility
https://www.readbyqxmd.com/read/26033044/the-fntb-promoter-polymorphism-rs11623866-as-a-potential-predictive-biomarker-for-lonafarnib-treatment-of-ovarian-cancer-patients
#15
MULTICENTER STUDY
Hagen Sjard Bachmann, Werner Meier, Andreas du Bois, Rainer Kimmig, Jan Dominik Kuhlmann, Winfried Siffert, Jalid Sehouli, Kerstin Wollschlaeger, Jens Huober, Peter Hillemanns, Alexander Burges, Barbara Schmalfeldt, Behnaz Aminossadati, Pauline Wimberger
AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced ovarian cancer. This study was performed as a genetic subgroup analysis of the AGO-OVAR-15 trial, and investigated the utility of the promoter polymorphism rs11623866 of the farnesyltransferase ß-subunit gene (FNTB) in predicting the clinical effectiveness of lonafarnib...
November 2015: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26028692/should-fallopian-tubes-be-removed-during-hysterectomy-procedures-a-statement-by-ago-ovar
#16
M Pölcher, S Hauptmann, C Fotopoulou, B Schmalfeldt, I Meinhold-Heerlein, A Mustea, I Runnebaum, J Sehouli
No abstract text is available yet for this article.
April 2015: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/25914073/opportunistic-salpingectomies-for-the-prevention-of-a-high-grade-serous-carcinoma-a-statement-by-the-kommission-ovar-of-the-ago
#17
REVIEW
Martin Pölcher, Steffen Hauptmann, Christina Fotopoulou, Barbara Schmalfeldt, Ivo Meinhold-Heerlein, Alexander Mustea, Ingo Runnebaum, Jalid Sehouli
The detection of premalignant cells in the epithelium of the fallopian tube has resulted in revolutionary theories regarding the origin of epithelial ovarian cancer (EOC). Serous tubal intra-epithelial carcinomas (STIC) have been detected in patients with BRCA 1 or 2 mutations and are considered as the most likely precursors of the high-grade serous ovarian cancer (HGSOC), which is the most common histological subtype in patients with EOC. A bilateral salpingo-oophorectomy is associated with a significant reduction in risk of developing EOC...
July 2015: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/25882474/less-sickness-with-more-motion-and-or-mental-distraction
#18
RANDOMIZED CONTROLLED TRIAL
Jelte E Bos
BACKGROUND: Motion sickness may reduce passenger comfort and crew performance. Countermeasures are dominated by medication with specific and often undesirable side effects. OBJECTIVE: To shown that sickness due to motion can be reduced by adding an inherent non-sickening vibration and by mental distraction. METHODS: Eighteen blindfolded subjects were exposed to 20 minutes of off-vertical axis rotation (OVAR). Vibration was added by means of a head rest...
2015: Journal of Vestibular Research: Equilibrium & Orientation
https://www.readbyqxmd.com/read/25852746/fecal-egg-counts-for-gastrointestinal-nematodes-are-associated-with-a-polymorphism-in-the-mhc-drb1-gene-in-the-iranian-ghezel-sheep-breed
#19
Rahman Hajializadeh Valilou, Seyed A Rafat, David R Notter, Djalil Shojda, Gholamali Moghaddam, Ahmad Nematollahi
Genetic variation among sheep breeds in resistance to gastrointestinal nematodes (GIN) has been demonstrated in several production environments. Relationships between the ovine major histocompatibility complex and resistance to GIN have been studied, but few studies have systematically examined this issue in less-developed and semi-arid regions. The aim of the current study was to explore associations between fecal worm egg counts (FEC) for several GIN and polymorphisms in the DRB1 gene. One hundred male lambs were selected at 4-6 months of age from weaned animals in five flocks (n = 20 per flock)...
2015: Frontiers in Genetics
https://www.readbyqxmd.com/read/25739827/the-prognostic-relevance-of-node-metastases-in-optimally-cytoreduced-advanced-ovarian-cancer
#20
Cornelia Bachmann, Sara Y Brucker, Bernhard Kraemer, Ralf Rothmund, Anette Staebler, Falko Fend, Diethelm Wallwiener, Eva-Maria Grischke
PURPOSE: To delineate the relevance of pelvic and para-aortic node involvement in optimally cytoreduced (residual tumour <1 cm) stage IIIC ovarian cancer patients. METHODS: Ninety-five consecutive optimally cytoreduced (R ≤ 1 cm) patients with primary stage IIIc ovarian cancer underwent stage-related surgery and got adjuvant platinum-based chemotherapy. Median follow-up: 53.5 months. All patients got systematic lymphadenectomy. On average, 24.7 pelvic and para-aortic lymph nodes were removed per patient (range 1-60 nodes)...
August 2015: Journal of Cancer Research and Clinical Oncology
keyword
keyword
7342
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"